Cefepime/Enmetazobactam
Complicated Urinary Tract Infections (cUTI)
Phase 3Active
Key Facts
Indication
Complicated Urinary Tract Infections (cUTI)
Phase
Phase 3
Status
Active
Company
About Allecra Therapeutics
Allecra Therapeutics is a French biotech addressing the global crisis of antimicrobial resistance (AMR) through the development of novel antibiotic combinations. Its lead asset, cefepime/enmetazobactam, has demonstrated superiority over the standard of care (piperacillin-tazobactam) in a pivotal Phase 3 trial for complicated urinary tract infections (cUTIs), positioning it for near-term regulatory submissions in the US and EU. Backed by a seasoned management team and European life science investors, the company is navigating the challenging but critically important antibiotic development landscape with a late-stage, high-need product candidate.
View full company profileTherapeutic Areas
Other Complicated Urinary Tract Infections (cUTI) Drugs
| Drug | Company | Phase |
|---|---|---|
| DIBI (IV) | Fe Pharmaceuticals | Pre-clinical |